807 related articles for article (PubMed ID: 10560596)
1. Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial.
Bensen WG; Fiechtner JJ; McMillen JI; Zhao WW; Yu SS; Woods EM; Hubbard RC; Isakson PC; Verburg KM; Geis GS
Mayo Clin Proc; 1999 Nov; 74(11):1095-105. PubMed ID: 10560596
[TBL] [Abstract][Full Text] [Related]
2. Treatment of painful temporomandibular joints with a cyclooxygenase-2 inhibitor: a randomized placebo-controlled comparison of celecoxib to naproxen.
Ta LE; Dionne RA
Pain; 2004 Sep; 111(1-2):13-21. PubMed ID: 15327804
[TBL] [Abstract][Full Text] [Related]
3. Upper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo.
Bensen WG; Zhao SZ; Burke TA; Zabinski RA; Makuch RW; Maurath CJ; Agrawal NM; Geis GS
J Rheumatol; 2000 Aug; 27(8):1876-83. PubMed ID: 10955327
[TBL] [Abstract][Full Text] [Related]
4. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial.
Simon LS; Weaver AL; Graham DY; Kivitz AJ; Lipsky PE; Hubbard RC; Isakson PC; Verburg KM; Yu SS; Zhao WW; Geis GS
JAMA; 1999 Nov; 282(20):1921-8. PubMed ID: 10580457
[TBL] [Abstract][Full Text] [Related]
5. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study.
Singh G; Fort JG; Goldstein JL; Levy RA; Hanrahan PS; Bello AE; Andrade-Ortega L; Wallemark C; Agrawal NM; Eisen GM; Stenson WF; Triadafilopoulos G;
Am J Med; 2006 Mar; 119(3):255-66. PubMed ID: 16490472
[TBL] [Abstract][Full Text] [Related]
6. The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus.
Sowers JR; White WB; Pitt B; Whelton A; Simon LS; Winer N; Kivitz A; van Ingen H; Brabant T; Fort JG;
Arch Intern Med; 2005 Jan; 165(2):161-8. PubMed ID: 15668361
[TBL] [Abstract][Full Text] [Related]
7. Celecoxib in the treatment of primary dysmenorrhea: results from two randomized, double-blind, active- and placebo-controlled, crossover studies.
Daniels S; Robbins J; West CR; Nemeth MA
Clin Ther; 2009 Jun; 31(6):1192-208. PubMed ID: 19695387
[TBL] [Abstract][Full Text] [Related]
8. Update on clinical developments with celecoxib, a new specific COX-2 inhibitor: what can we expect?
Geis GS
Scand J Rheumatol Suppl; 1999; 109():31-7. PubMed ID: 10422544
[TBL] [Abstract][Full Text] [Related]
9. Comparative efficacy and safety of celecoxib and naproxen in the treatment of osteoarthritis of the hip.
Kivitz AJ; Moskowitz RW; Woods E; Hubbard RC; Verburg KM; Lefkowith JB; Geis GS
J Int Med Res; 2001; 29(6):467-79. PubMed ID: 11803730
[TBL] [Abstract][Full Text] [Related]
10. Celecoxib for the treatment of pain and inflammation: the preclinical and clinical results.
Tindall E
J Am Osteopath Assoc; 1999 Nov; 99(11 Suppl):S13-7. PubMed ID: 10643176
[TBL] [Abstract][Full Text] [Related]
11. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis.
Steinbach G; Lynch PM; Phillips RK; Wallace MH; Hawk E; Gordon GB; Wakabayashi N; Saunders B; Shen Y; Fujimura T; Su LK; Levin B; Godio L; Patterson S; Rodriguez-Bigas MA; Jester SL; King KL; Schumacher M; Abbruzzese J; DuBois RN; Hittelman WN; Zimmerman S; Sherman JW; Kelloff G
N Engl J Med; 2000 Jun; 342(26):1946-52. PubMed ID: 10874062
[TBL] [Abstract][Full Text] [Related]
12. Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis.
Goldstein JL; Correa P; Zhao WW; Burr AM; Hubbard RC; Verburg KM; Geis GS
Am J Gastroenterol; 2001 Apr; 96(4):1019-27. PubMed ID: 11316141
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of the COX-2 specific inhibitor valdecoxib in the management of osteoarthritis of the hip: a randomized, double-blind, placebo-controlled comparison with naproxen.
Makarowski W; Zhao WW; Bevirt T; Recker DP
Osteoarthritis Cartilage; 2002 Apr; 10(4):290-6. PubMed ID: 11950252
[TBL] [Abstract][Full Text] [Related]
14. Celecoxib: a COX-2 inhibitor.
Andrews SA; Wallace CK; Davis RL
Am J Manag Care; 1999 Apr; 5(4):511-8; quiz 522-4. PubMed ID: 10387389
[No Abstract] [Full Text] [Related]
15. Antiinflammatory and analgesic efficacy of COX-2 specific inhibition: from investigational trials to clinical experience.
Bensen WG
J Rheumatol Suppl; 2000 Oct; 60():17-24. PubMed ID: 11032098
[TBL] [Abstract][Full Text] [Related]
16. Celecoxib plus aspirin versus naproxen and lansoprazole plus aspirin: a randomized, double-blind, endoscopic trial.
Goldstein JL; Cryer B; Amer F; Hunt B
Clin Gastroenterol Hepatol; 2007 Oct; 5(10):1167-74. PubMed ID: 17916545
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and tolerability of lumiracoxib in the treatment of osteoarthritis of the knee: a 13-week, randomized, double-blind comparison with celecoxib and placebo.
Sheldon E; Beaulieu A; Paster Z; Dutta D; Yu S; Sloan VS
Clin Ther; 2005 Jan; 27(1):64-77. PubMed ID: 15763607
[TBL] [Abstract][Full Text] [Related]
18. Longer use of COX-2-specific inhibitors compared to nonspecific nonsteroidal antiinflammatory drugs: a longitudinal study of 3639 patients in community practice.
Wolfe F; Michaud K; Burke TA; Zhao SZ
J Rheumatol; 2004 Feb; 31(2):355-8. PubMed ID: 14760808
[TBL] [Abstract][Full Text] [Related]
19. New directions in symptomatic therapy for patients with osteoarthritis and rheumatoid arthritis.
Hochberg MC
Semin Arthritis Rheum; 2002 Dec; 32(3 Suppl 1):4-14. PubMed ID: 12528069
[TBL] [Abstract][Full Text] [Related]
20. Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a 13 week, randomised, double blind study versus placebo and celecoxib.
Tannenbaum H; Berenbaum F; Reginster JY; Zacher J; Robinson J; Poor G; Bliddal H; Uebelhart D; Adami S; Navarro F; Lee A; Moore A; Gimona A
Ann Rheum Dis; 2004 Nov; 63(11):1419-26. PubMed ID: 15020310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]